To take the CE quiz, click here.
This quiz is open until November 2024.
DVM, DACVS, DACVSMR
Dr. Millis received his BS and DVM from Cornell University and his MS from the University of Florida. He completed an internship and surgery residency at Michigan State University. He is a professor of orthopedic surgery at the University of Tennessee College of Veterinary Medicine, the director of the CARES Center for Veterinary Sports Medicine, and a primary faculty member of the University of Tennessee Certificate Program in Canine Rehabilitation, which received the Outstanding Non-Credit Program Award from the Association for Continuing Higher Education. He is also past president of the International Association of Veterinary Rehabilitation and Physical Therapy and the founder of MyLameDog.com and MyLameDogsVet.com, online resources regarding common orthopedic conditions. He is the author of over 60 publications, 80 textbook chapters, and 110 abstracts/proceedings.Read Articles Written by Darryl Millis
Osteoarthritis (OA) is one of the most common conditions in dogs, affecting up to 75% of adult medium-size and large dogs.1-3 One corporate report of OA in dogs estimates a 66% increase in the past decade.4 Yet a recent study of OA in primary care practices suggested that the prevalence of OA was only 2.5%, and the median age at the time of diagnosis was 10.5 years.1 This suggests that canine patients are not screened at an early age, owners are not recognizing clinical signs, and veterinarians should be assessing dogs for OA at an earlier age and instituting treatment.
Consequences of Osteoarthritis
Chronic OA results in pain, lameness, decreased joint range of motion, muscle atrophy, and decreased function and activity. Dogs often become overweight or obese as a result of decreased activity.
Identification of Osteoarthritis
Canine OA most commonly affects the shoulder, tarsus, and hip. Unfortunately, owners associate OA with old age when, in fact, many cases of OA may be attributed to conditions that develop in dogs younger than 1 year, such as hip dysplasia, elbow dysplasia, and osteochondritis dissecans. Therefore, it is essential for the lifelong health of the dog that veterinarians evaluate large- and giant-breed dogs for these conditions at 6 to 8 months of age. Surgical correction that may slow the progression of OA is often possible if conditions are identified early and appropriate intervention is performed. As patients age, they should be checked during annual evaluations for OA, especially of the hips, elbows, and hocks. In addition, cranial cruciate ligament disease may result in secondary OA.
Owners should be asked about their dog’s ability to function in the home environment (BOX 1). Common findings with OA include difficulty rising after rest, difficulty negotiating stairs, reluctance to play, and lameness noted while walking or trotting. Validated questionnaires are available to further quantitate function, such as the Canine Brief Pain Inventory and the Liverpool Osteoarthritis in Dogs. One study found that owners did not recognize clinical signs prior to their dog’s OA diagnosis, and some waited months before going to a veterinarian.5
Dogs should be evaluated at a stance, walk, and trot, as well as in a sitting position. Visual assessment of mild lameness is challenging, necessitating careful observation of gait while the dog is walking and trotting in an undistracted straight line. Further evaluation may include having the dog ascend and descend stairs and rise from a sitting position. Even if the gait appears symmetric, a thorough orthopedic examination should be performed because subtle lameness may not be detected. Also, developmental conditions may be bilateral, resulting in symmetric lameness in both limbs.
A thorough orthopedic examination begins with the dog in a standing position to palpate both forelimbs and then both pelvic limbs simultaneously for muscle atrophy and joint effusion. In-depth evaluation of joints may be performed with the dog standing or, preferably, in lateral recumbency. Beginning distally with the toes and proceeding proximally, each joint should be systematically evaluated for periarticular swelling, joint effusion, joint instability, crepitus, range of motion, and pain with manipulation. Muscle mass usually precludes assessment of the hip and shoulder joints for swelling or effusion. Any loss of range of motion or pain at the end of range generally indicates a problem with the joint.
Radiographs should be taken of joints with suspected OA, but if there are radiographic signs of OA, there are already biochemical or biomechanical changes to cartilage (FIGURE 1). Common radiographic findings include subchondral sclerosis of bone, osteophytes, enthesophytes, and joint effusion. Specialized imaging, such as PennHIP for hip dysplasia or computed tomography of elbows, may result in earlier diagnosis of conditions in young dogs.
Components of Multimodal Management
The pathophysiology of OA is complex and involves all components of the joint organ. It is unreasonable to expect that a single treatment will result in optimal improvement. Therefore, a multimodal approach to OA management is crucial to address multiple biochemical pathways and functional deficits.
The traditional management of canine OA includes anti-inflammatory and analgesic medications, disease-modifying OA agents, weight management, exercise modification, physical rehabilitation modalities, environment modifications, and surgical procedures (TABLE 1). Managing OA is a lifelong commitment that is focused on decreasing inflammation and disease progression and improving muscle strength and endurance; joint range of motion, performance, and function; and quality of life.
Weight loss can be one of the cheapest and safest methods of treating OA. Noticeable improvement may be seen after loss of 6.9% of body weight.6 For comparison, it has been suggested that a change of 1 unit on a 9-point body condition score approximates a 5% change in body weight.7
Nonsteroidal Anti-Inflammatory Drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are important to reduce pain and inflammation. However, no drug is effective in all dogs, and different NSAIDs have varying effects in different patients, both in efficacy and adverse events. All have shown efficacy in clinical studies. More selective cyclooxygenase (COX)-2 inhibitors, such as deracoxib, firocoxib, and robenacoxib, may have fewer side effects than nonselective COX-2 inhibitors, as suggested by adverse event profiles in clinical studies. Another NSAID, grapiprant, does not inhibit prostaglandin production, but is an EP4 prostaglandin receptor antagonist, and may result in fewer serious adverse events.8 Still, all NSAIDs have the potential for adverse events, including gastrointestinal, hepatic, and renal effects. The clinical pharmacology of NSAIDs has been reviewed elsewhere.9
Dose reduction has been suggested as a means of reducing adverse effects of NSAIDs. This may result in reduced efficacy of the NSAID, as suggested by one review of dose reduction of meloxicam.10
A meta-analysis of adverse events associated with NSAIDs indicated that the most common adverse events included vomiting, diarrhea, and anorexia.11 Another study evaluated the adverse effects of long-term administration of carprofen, etodolac, and meloxicam for 90 days.12 Serum gamma-glutamyltransferase activity significantly increased at day 30 in dogs treated with etodolac and meloxicam. Gastric lesions were detected in all dogs treated with etodolac, and 1 of 6 treated with carprofen.
Renal effects of NSAIDs may also be important. Dogs have higher basal levels of COX-2 expression in the kidney than humans. In dogs with chronic kidney disease, COX-2 expression increases and synthesis of prostaglandins shifts to the COX-2 pathway. Therefore, NSAIDs that target COX-2 may adversely affect renal function in dogs with chronic kidney disease.13
Other Analgesic Medications
Amantadine is an oral N-methyl-D-aspartate (NMDA) receptor antagonist that may be useful when given with an NSAID.14 Central sensitization, which may occur with chronic pain, is mediated in part by activation of NMDA receptors. Blocking these receptors may reduce central nervous system hyperresponsiveness, allowing other analgesics to function more effectively. Amantadine may be given on a continual basis if needed, although in some cases it can be given daily for 7 to 14 days and then discontinued until pain worsens. Elimination is almost exclusively via the kidneys, therefore dose reductions should be considered in cases of renal disease. Side effects are rare but can include agitation or diarrhea.
Gabapentin is also sometimes used as an adjunct pain medication for OA; however, its efficacy for acute and chronic pain has been questioned.15,16 Its best application may be for neuropathic pain. Pregabalin has also been used for OA. Possible side effects may include sedation and weight gain.
Studies have shown tramadol to be ineffective in treating OA. In one study, treatment with tramadol provided no clinical benefit for dogs with OA of the elbow or stifle joint,17 confirming the results of a prior study.18
The use of opioid medications, including codeine preparations, has been suggested in dogs with pain due to OA. One study compared acetaminophen and codeine (1.6 to 2 mg codeine/kg) to carprofen in an acute urate crystal synovitis model.19 Dogs receiving carprofen had less lameness than those receiving acetaminophen and codeine. Further, oral codeine is not absorbed as well in dogs as in humans.16
Many nutritional supplements are available, but consumers should realize that products may not contain what the label indicates. Veterinarians are encouraged to use products that have been tested by independent laboratories. The use of common nutraceuticals has been reviewed elsewhere.7,20
Omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are associated with positive effects on OA, demonstrating increased weight bearing and reduction in NSAID dose needed to maintain comfort.7 In addition, they reduce prostaglandin E2 in cartilage, compete with arachidonic acid in the COX and lipoxygenase pathways, and result in lower levels of inflammatory leukotrienes. Doses of 230 to 370 mg per kilogram of lean body weight(0.75) have been recommended for EPA and DHA.21 In addition to EPA and DHA supplements, therapeutic diets containing omega-3 fatty acids are also effective. A study of a veterinary therapeutic diet high in omega-3 fatty acids administered to dogs with OA showed significantly higher peak vertical forces after 13 weeks compared with baseline and dogs fed the control diet.22
Green-lipped mussel has also shown to have benefit in dogs with OA.7 It also contains omega-3 fatty acids, but there may be other mechanisms of action, including modulation of chondrocyte activity and anti-inflammatory effects.
Avocado/soybean unsaponifiables have anabolic, anticatabolic, and anti-inflammatory effects on chondrocytes.23 They may increase transforming growth factor-β and collagen and aggrecan synthesis while inhibiting nuclear factor kappa B (NF-κB) activation, interleukin (IL)-1β–induced collagenase, matrix metalloproteinase activity, nitric oxide, and prostaglandin E2.
Undenatured type II collagen (UC-II) is a relatively new nutraceutical.24 One study showed that daily treatment of arthritic dogs with UC alleviated arthritis-associated pain and lameness. These effects were noted when UC was given alone or in combination with glucosamine and chondroitin, although the results were better when administered alone.25
Glucosamine and chondroitin are commonly used, but data on appropriate dose and efficacy are scarce.26 Nevertheless, in one survey, veterinarians recommended using glucosamine/chondroitin products and omega-3 fatty acids more often than other products for their patients and their own pets.27 One recent study indicated that glucosamine and chondroitin administered for 70 days resulted in improvements in subjective scores for pain, weight bearing, and overall condition from pretreatment values.28 Other studies have shown little or no effect.
Boswellia is purported to inhibit 5-lipoxygenase and matrix metalloproteinases and to decrease tumor necrosis factor and IL-1β. Boswellia was evaluated in 24 dogs in a multicenter study, with improved lameness and pain noted in 17 dogs.29 However, this study was not randomized or placebo-controlled.
Polysulfated glycosaminoglycans (PSGAGs) are disease-modifying osteoarthritis drugs that are anti-inflammatory, inhibit matrix metalloproteinases within the joint, and have a positive effect on hyaluronic acid (HA) and glycosaminoglycan synthesis in diseased joints. PSGAGs have many beneficial mechanisms and are generally effective in improving lameness,30,31 but they must be administered by injection.
Intra-articular treatments have increased in popularity. HA, platelet-rich plasma (PRP), mesenchymal stem cells (MSC), and corticosteroids are possible intra-articular therapies.
MSC therapy for dogs with OA has been recently reviewed.32 Five studies demonstrated improved pain, range of motion, and visual analogue scale scores in dogs treated with adipose-derived MSC, MSC plus PRP, MSC plus HA, or stromal vascular fraction. One study suggested better results with MSC than with PRP 6 months after treatment. Improvement persisted for 3 to 6 months. Future studies should evaluate MSC with placebo controls and multiple intra-articular injections in combination with other therapies, such as PRP or HA.
One study compared intra-articular treatment with HA, triamcinolone, and PRP in dogs with hip dysplasia.33 Improvement in several validated questionnaires and weight bearing at a stance had longer duration of effect for dogs treated with HA and PRP, while triamcinolone had the greatest effect on pain improvement (95% improvement over controls). Dogs treated with PRP and HA had 57% to 81% improvement in functional evaluation and impairments due to OA. Other studies also support the use of PRP for OA.34,35
Exercise is recommended as one of the main treatments for OA in people, and anecdotal observations suggest that it is useful in dogs. A recent review of human literature found that 90% of articles regarding exercise-induced analgesia demonstrated positive effects of exercise, and analgesia was demonstrated with running, swimming, and resistance training.36 Although specific studies of the amount and type of exercise do not yet exist in dogs, low-impact, regular exercise titrated to the dog’s ability is logical. If appropriate, the amount of increase in weekly low-impact exercise may be up to 5% to 10% in dogs with severe OA, as long as the dog does not worsen with increased activity. Underwater treadmill walking is appropriate for dogs with OA due to the buoyancy, resistance, and hydrostatic pressure provided by water. Caution should be used with swimming for severely affected dogs because the joints move rapidly during swimming; underwater treadmill walking allows controlled velocity and simulates more normal joint flexion and extension.
Cold decreases blood flow, inflammation, hemorrhage, and metabolic rate.37 Studies of cryotherapy and OA suggest positive benefits, including less stiffness and pain and improved joint range of motion.
Heat increases blood flow and tissue extensibility and may decrease pain, muscle spasm, and joint stiffness.37 Heat is contraindicated if swelling or edema are present and may increase inflammation.
Extracorporeal Shock Wave Therapy
Extracorporeal shock wave therapy (ESWT) is the transmission of high-pressure acoustic waves through tissues to a target area, where energy is released and a variety of growth factors are produced. Studies of ESWT for OA have shown positive benefits with increases in ground reaction forces.38,39
Transcutaneous Electrical Nerve Stimulation
Transcutaneous electrical nerve stimulation (TENS) provides analgesia through several mechanisms of action, including the “gate theory” of pain control.40 A single TENS treatment in dogs with stifle OA can result in significantly improved weight bearing. While daily application is likely necessary, it may give added benefit to medications and may be used in patients that cannot tolerate certain medications.
Therapeutic laser (TL) treatment affects intracellular photochemical reactions. Results of TL in patients with OA have been mixed. One study in dogs with elbow OA treated with 10 to 20 J/cm2 of TL or a placebo to both elbows for 6 weeks showed a reduction in NSAID dose and lameness scores in TL-treated dogs.41 Another study of TL using 10 J/cm2 versus placebo failed to show an improvement in ground reaction forces in dogs with hip or stifle OA.42
If TL is used, the hair should be clipped to improve transmission of photons to target tissues, and consideration should be given to the color of the skin and the depth of the tissues.43,44
Many surgical procedures have evolved to help manage OA, including total hip, stifle, and elbow replacement. Procedures for severe medial compartment disease of the elbow secondary to fragmented medial coronoid process include ulnar osteotomy, proximal abducting ulnar osteotomy, sliding humeral osteotomy, and the canine unicompartmental elbow implant. Arthrodesis may also be a choice with severe carpal or tarsal OA.
Altering the environment may be helpful for arthritic dogs. A soft, well-padded bed should be provided, along with good flooring to prevent slips and falls. Owners can minimize stair climbing through the use of fixed ramps. Portable ramps are available to assist dogs with getting in and out of vehicles. Additional harnesses and support devices are also available. Owners should avoid overdoing activities and prevent excessive play with other pets.
Other potential treatments for OA include acupuncture, chiropractic, massage, pulsed electromagnetic field therapy, prolotherapy, joint mobilization and manipulation, radiation therapy,45 and nuclear magnetic resonance treatment.46,47
OA is common in dogs. Management involves multiple modalities and must be tailored to each patient and its owner. Weight control, medications, joint supplements, and physical rehabilitation are the main components of OA management. When selecting treatments, veterinarians should consider the efficacy, safety profile, mechanism of action, and patient response for each. Although not all dogs respond equally to all treatments, cooperation among all parties is vital to carry out an appropriate management program, and monitoring is essential to help with decision-making for further treatment.
- Anderson KL, O’Neill DG, Brodbelt DC, et al. Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018;8(1):5641. doi:10.1038/s41598-018-23940-z
- Craig LE, Reed A. Age-associated cartilage degeneration of the canine humeral head. Vet Pathol. 2012;50(2):264-268. doi:10.1177/0300985812452584
- Millis DL, Tichenor M, Hecht S. Prevalence of osteoarthritis in dogs undergoing routine dental prophylaxis. In: Proceedings of the 8th Meeting of the International Association of Veterinary Rehabilitation and Physical Therapy. 2014:133.
- Osteoarthritis in pets on the rise alongside obesity epidemic. Veterinary Practice News. June 25, 2019. Accessed March 15, 2021.veterinarypracticenews.com/osteoarthritis-in-pets-on-the-rise-alongside-obesity-epidemic
- Belshaw Z, Dean R, Asher L. Could it be osteoarthritis? How dog owners and veterinary surgeons describe identifying canine osteoarthritis in a general practice setting. Preventive Vet Med. 2020;185:105198. doi:10.1016/j.prevetmed.2020.105198
- Marshall WG, Hazewinkel HAW, Mullen D, et al. The effect of weight loss on lameness in obese dogs with osteoarthritis. Vet Res Commun. 2010;34(3):241-253.
- Johnson KA, Lee AH, Swanson KS. Nutrition and nutraceuticals in the changing management of osteoarthritis for dogs and cats. JAVMA. 2020;256(12):1335-1341.
- Rausch-Derra L, Huebner M, Wofford J, Rhodes L. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Intern Med. 2016;30:756-763.
- KuKanich B, Bidgood T, Knesl O. Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. Vet Anaesth Analg. 2012;39(1):69-90. doi:10.1111/j.1467-2995.2011.00675.x
- Wernham BG, Trumpatori B, Hash J, et al. Dose reduction of meloxicam in dogs with osteoarthritis-associated pain and impaired mobility. J Vet Intern Med. 2011;25:1298-1305.
- Monteiro-Steagall BP, Steagall PVM, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med. 2013;27:1011-1019.
- Stelio PL, Luna AC, Basílio PV, et al. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res. 2007;68(3):258-264.
- Lomas AL, Grauer GF. The renal effects of NSAIDs in dogs. JAAHA. 2015;51(3):197-203. doi:10.5326/JAAHA-MS-6239
- Lascelles BDX, Gaynor JS, Smith ES, et al. Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. J Vet Intern Med. 2008;22:53-59.
- Wagner AE, Mich PM, Uhrig SR, Hellyer PW. Clinical evaluation of perioperative administration of gabapentin as an adjunct for postoperative analgesia in dogs undergoing amputation of a forelimb. JAVMA. 2010;236(7):751-756.
- KuKanich B. Outpatient oral analgesics in dogs and cats beyond nonsteroidal antiinflammatory drugs: an evidence-based approach. Vet Clin Small Anim Pract. 2013;43(5):1109-1125. doi:10.1016/j.cvsm.2013.04.007
- Budsberg SC, Torres BT, Kleine SA, et al. Lack of effectiveness of tramadol hydrochloride for the treatment of pain and joint dysfunction in dogs with chronic osteoarthritis. JAVMA. 2018;252(4):427-432.
- Westling M, Millis DL. The effect of oral tramadol on ground reaction forces in dogs with experimentally induced osteoarthritis. Vet Comp Orthop Traumatol. 2012;4:A22.
- Budsberg SC, Kleine SA, Norton MM, et al. Comparison of the effects on lameness of orally administered acetaminophen-codeine and carprofen in dogs with experimentally induced synovitis. Am J Vet Res. 2020;81(8):627-634.
- Comblain F, Serisier S, Barthelemy N, et al. Review of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014. J Vet Pharmacol Ther. 2016;39(1):1-15. doi:10.1111/jvp.12251
- Bauer JE. Therapeutic use of fish oils in companion animals. JAVMA. 2011;239(11):1441-1451.
- Moreau M, Troncy E, del Castillo JR, et al. Effects of feeding a high omega-3 fatty acids diet in dogs with naturally occurring osteoarthritis. J Anim Physiol Anim Nutr (Berl). 2013;97(5):830-837.
- DiNubile NA. A potential role for avocado- and soybean-based nutritional supplements in the management of osteoarthritis: a review. Phys Sportsmed. 2010;38:(2):71-81. doi:10.3810/psm.2010.06.1785
- Deparle A, Gupta RC, Canerdy TD. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. J Vet Pharmacol Ther. 2005;28(4):385-390.
- D’Altilio M, Peal A, Alvey M. Therapeutic efficacy and safety of undenatured type ii collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. Toxicol Mech Methods. 2007;17(4):189-196.
- Bhathal A, Spryszak M, Louizos C, Frankel G. Glucosamine and chondroitin use in canines for osteoarthritis: a review. Open Vet J. 2017;7(1):36-49.
- Elrod SM, Hofmeister EH. Veterinarians’ attitudes towards use of nutraceuticals. Can J Vet Res. 2019;83(4):291-297.
- McCarthy G, O’Donovan J, Jones B, et al. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J. 2007;174(1):54-61.
- Reichling J, Schmokel H, Fitzi J, et al. Dietary support with Boswellia resin in canine inflammatory joint and spinal disease. Schweiz Arch Tierheilkd. 2004;146(2):71-79.
- Fujiki M, Shineha J, Yamanokuchi K, et al. Effects of treatment with polysulfated glycosaminoglycan on serum cartilage oligomeric matrix protein and C-reactive protein concentrations, serum matrix metalloproteinase-2 and -9 activities, and lameness in dogs with osteoarthritis. Am J Vet Res. 2007;68(8):827-833.
- Food and Drug Administration. Freedom of Information Summary for Adequan Canine. July 15, 1997. Accessed July 2021. animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/3696
- Hoffman AM, Dow SW. Concise review: stem cell trials using companion animal disease models. Stem Cells. 2016;34(7):1709-1729.
- Alves JC, Santos A, Jorge P, et al. Intraarticular triamcinolone hexacetonide, stanozolol, Hylan G-F 20 and platelet concentrate in a naturally occurring canine osteoarthritis model. Sci Rep. 2021;11(1):3118. doi:10.1038/s41598-021-82795-z
- Vilar J, Manera M, Santana A, et al. Effect of leukocyte-reduced platelet-rich plasma on osteoarthritis caused by cranial cruciate ligament rupture: a canine gait analysis model. PLoS ONE. 2018;13(3): e0194752. doi:10.1371/journal.pone.0194752
- Fahie MA, Ortolano GA, Guercio V, et al. A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs. JAVMA. 2013;243(9):1291-1297.
- Lesnak JB, Sluka KA. Mechanism of exercise-induced analgesia: what we can learn from physically active animals. Pain Rep. 2020;5(5):e850.
- Millis DL, Levine D. Superficial thermal modalities. In: Canine Physical Therapy and Rehabilitation. 2nd ed. Elsevier; 2013:312-327.
- Millis DL, Drum M, Whitlock D. Complementary use of extracorporeal shock wave therapy on elbow osteoarthritis in dogs. Veterinary Orthopedic Society. Vet Comp Orthop Traumatol. 2011;24(3):A1.
- Souza ANA, Ferreira MP, Hagen SCF, et al. Radial shock wave therapy in dogs with hip osteoarthritis. Vet Comp Orthop Traumatol. 2016;29(2):108-114. doi:10.3415/VCOT-15-01-0017
- Millis DL, Levine D. Electrical stimulation. In: Canine Physical Therapy and Rehabilitation. 2nd ed. Elsevier; 2013:342-358.
- Looney AL, Huntingford JL, Blaeser LL, Mann S. A randomized blind placebo-controlled trial investigating the effects of photobiomodulation therapy (PBMT) on canine elbow osteoarthritis. Can Vet J. 2018;59(9):959-966.
- Millis DL, Drum M. The effect of complementary treatments in dogs with osteoarthritis of the hip or stifle. In: Proceedings of the 4th Veterinary European Veterinary Rehabilitation Association. 2015:127.
- Hochman-Elam LN, Heidel RE, Shmalberg JW. Effects of laser power, wavelength, coat length, and coat color on tissue penetration using photobiomodulation in healthy dogs Can J Vet Res. 2020;84(2):131-137.
- McCarthy D, Millis DL, Odoi A. Variables affecting class IV laser absorbance. Acta Vet Scand. 2019;61(suppl 1):A9.
- Kapatkin AS, Nordquist B, Garcia TC, et al. Effect of single dose radiation therapy on weight-bearing lameness in dogs with elbow osteoarthritis. Vet Comp Orthop Traumatol. 2016;29(4):338-343. doi:10.3415/VCOT-15-11-0183
- Huels N, Harms O, Keim D, et al. Treatment of the clinical symptoms of osteoarthritis in the elbow joints of dogs using nuclear magnetic resonance therapy: a randomized, double-blinded trial. Front Vet Sci. 2020;7:500278. doi:10.3389/fvets.2020.500278
- Mucha M, Virac I, Lang C, et al. Treatment of the clinical symptoms caused by osteoarthritis using nuclear magnetic resonance (MBST) in dogs-a randomized trial. Wien Tierarztl Monatsschr. 2017;104:109-115. doi:10.1186/s12917-016-0840-3
This article has been submitted for RACE approval for 1 hour of continuing education credit and will be opened for enrollment when approval has been received. To receive credit, take the test for free by visiting vetfolio.com and entering the title of the article in the search bar. Free registration is required. Questions and answers online may differ from those below. Tests are valid for 2 years from the date of approval.
Osteoarthritis (OA) is one of the most common conditions in dogs and can result in issues such as lameness and decreased joint range of motion. Veterinary practitioners should understand the process for early identification of OA in order to develop a multimodal treatment plan that aims to delay disease progression, decrease inflammation, and ultimately improve the patient’s quality of life.
Readers will learn how to identify common signs of OA and the role and benefits of the components of multimodal management, including medications, disease-modifying OA agents, weight management, exercise modification, physical rehabilitation modalities, environment modifications, and surgical procedures.
1. Many underlying causes of osteoarthritis (OA) can first be identified when a dog is
a. Younger than 1 year
b. 2 to 4 years of age
c. 5 to 8 years of age
d. Older than 10 years
2. Although OA is common in dogs, it often goes undiagnosed until its later stages due to a lack of
a. Owner recognition
c. Clinical assessment
d. All of the above
3. Which statement regarding clinical assessment for OA is true?
a. Visual assessment of gait and lameness is a sensitive measure
b. Radiographic signs of early osteoarthritis indicate that the articular cartilage is undamaged
c. A complete orthopedic evaluation should be performed even if the gait appears normal
d. Dogs should be evaluated for lameness secondary to osteoarthritis only at a trot
4. Which of the following treatments has shown efficacy in clinical studies to improve the clinical signs associated with OA?
a. Omega-3 fatty acids
c. Polysulfated glycosaminoglycans
d. All of the above
5. Grapiprant inhibits which of the following?
c. EP4 prostaglandin receptor
5. Which of the following is a goal of OA treatment?
a. Restoration of normal joint function
c. Joint replacement
d. Weight gain
7. Consequences of OA include
a. Hip dysplasia
b. Elbow dysplasia
c. Osteochondritis dissecans
8. Weight loss of approximately _____ has been shown to result in noticeable improvement in clinical signs of osteoarthritis in obese dogs.
9. Amantadine is perhaps best used for
a. Decreasing central nervous system hyperresponsiveness
b. Neuropathic pain
c. Pain management in dogs with kidney disease
d. Dogs that cannot tolerate NSAIDs
10. Which of the following intra-articular treatments may be useful in dogs with osteoarthritis?
a. Platelet-rich plasma
b. Mesenchymal stem cells
d. All of the above